NZ729878B2 - Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alpha4beta7 integrin blocking antibodies - Google Patents

Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alpha4beta7 integrin blocking antibodies Download PDF

Info

Publication number
NZ729878B2
NZ729878B2 NZ729878A NZ72987815A NZ729878B2 NZ 729878 B2 NZ729878 B2 NZ 729878B2 NZ 729878 A NZ729878 A NZ 729878A NZ 72987815 A NZ72987815 A NZ 72987815A NZ 729878 B2 NZ729878 B2 NZ 729878B2
Authority
NZ
New Zealand
Prior art keywords
chemokine receptor
receptor inhibitor
ccr9
ccr9 chemokine
integrin blocking
Prior art date
Application number
NZ729878A
Other versions
NZ729878A (en
Inventor
Karen Ebsworth
Joanne Tan
Yu Wang
Yibin Zeng
Penglie Zhang
Original Assignee
Chemocentryx Inc
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Priority to NZ768528A priority Critical patent/NZ768528A/en
Priority claimed from PCT/US2015/054077 external-priority patent/WO2016057424A1/en
Publication of NZ729878A publication Critical patent/NZ729878A/en
Publication of NZ729878B2 publication Critical patent/NZ729878B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49

Abstract

Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-a4p7 integrin antibody such as vedolizumab. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-a4p7 integrin antibody.

Claims (25)

Claims:
1. Use of a CCR9 chemokine receptor inhibitor in the preparation of a ment for treating inflammatory bowel disease in a human, wherein the medicament is to be administered in combination with an anti-a4ß7 integrin blocking antibody, wherein the CCR9 chemokine receptor tor is: vercirnon (Traficet-EN™); or or a pharmaceutically acceptable salt thereof.
2. The use of claim 1, wherein the matory bowel disease is Crohn’s disease (CD) or ulcerative colitis (UC).
3. The use of claim 1, wherein the 4ß7 integrin blocking antibody is vedolizumab (ENYVIO®).
4. The use of claim 1, wherein the medicament is to be administered with the anti-a4ß7 integrin blocking antibody in a combination formulation.
5. The use of claim 1, wherein the medicament is to be sequentially administered with the anti-a4ß7 integrin blocking dy.
6. The use of claim 5, wherein the medicament is to be administered prior to administration of the anti-a4ß7 in blocking antibody.
7. The use of claim 5, wherein the medicament is to be administered after administration of the anti-a4ß7 integrin blocking antibody.
8. The use of any one of claims 1 to 7, wherein the CCR9 chemokine receptor inhibitor or a pharmaceutically acceptable salt thereof.
9. The use of any one of claims 1 to 7, wherein the CCR9 chemokine receptor inhibitor is vercirnon (Traficet-EN™).
10. A composition for treating or reducing the development of inflammatory bowel e in a human, said composition sing a therapeutically effective amount of a CCR9 chemokine receptor inhibitor, a eutically ive amount of an anti-a4ß7 integrin blocking antibody, and a pharmaceutically acceptable carrier or excipient, wherein the CCR9 ine receptor inhibitor is: vercirnon (Traficet-EN™); or or a pharmaceutically acceptable salt thereof.
11. The composition of claim 10, wherein the anti-a4ß7 integrin blocking antibody is vedolizumab (ENYVIO®).
12. The composition of claim 10 or claim 11, wherein the CCR9 chemokine receptor inhibitor is or a pharmaceutically able salt thereof.
13. The composition of claim 10 or claim 11, wherein the CCR9 chemokine receptor inhibitor is vercirnon (Traficet-EN™).
14. Use of a CCR9 chemokine receptor inhibitor and an anti-a4ß7 integrin blocking antibody in the manufacture of a medicament for treating or reducing the development of inflammatory bowel disease in a human, wherein the medicament is in the form of a kit, said kit comprising: a therapeutically effective amount of the CCR9 chemokine receptor inhibitor, and a therapeutically effective amount of the anti-a4ß7 integrin blocking antibody, n the CCR9 chemokine receptor inhibitor is: vercirnon cet-EN™); or or a pharmaceutically acceptable salt thereof.
15. The use of claim 14, wherein the CCR9 chemokine or inhibitor and the anti- a4ß7 integrin blocking dy are to be sequentially administered.
16. The use of claim 14, wherein the CCR9 chemokine receptor inhibitor and the anti- a4ß7 in blocking antibody are to be concomitantly administered.
17. The use of claim 14, wherein the anti-a4ß7 integrin blocking antibody is vedolizumab (ENYVIO®).
18. The use of any one of claims 14 to 17, wherein the CCR9 chemokine or inhibitor is or a pharmaceutically acceptable salt thereof.
19. The use of any one of claims 14 to 17, wherein the CCR9 chemokine receptor inhibitor is vercirnon (Traficet-EN™).
20. Use of an anti-a4ß7 integrin blocking dy in the preparation of a medicament for ng inflammatory bowel disease in a human, wherein the medicament is to be administered in combination with a CCR9 chemokine receptor inhibitor, wherein the CCR9 chemokine or inhibitor is: vercirnon (Traficet-EN™); or or a pharmaceutically acceptable salt thereof.
21. The use of claim 20, wherein the CCR9 chemokine receptor inhibitor and the anti- a4ß7 integrin blocking dy are to be sequentially stered.
22. The use of claim 20, wherein the CCR9 chemokine receptor inhibitor and the anti- a4ß7 integrin blocking antibody are to be concomitantly administered.
23. The use of claim 20, wherein the anti-a4ß7 integrin ng antibody is vedolizumab (ENYVIO®).
24. The use of any one of claims 20 to 23, wherein the CCR9 chemokine receptor inhibitor is or a pharmaceutically acceptable salt thereof.
25. The use of any one of claims 20 to 23, wherein the CCR9 chemokine receptor tor is vercirnon (Traficet-EN™). ChemoCentryx, Inc. By the Attorneys for the Applicant SPRUSON & FERGUSON xt.xxx\txtt‘x‘x?ttxtxt mh V .OE ..23.3.x?Zt.t.t.t.t.t.t.t.xxu.xxxx‘x..x..x‘xt.t.xxxxxxxxxxxxx‘xwxxxtxxtxxttttx??tttx §§i§§§ §1&3{3‘23 \- 3§§ $s§$§§§§§ t‘tx??txtxttt . .\\\\\\\\\\\xx.\\\\\\\\»\\.\\\\\»\\s‘xx\\\\\\\\\\\\\\»\\\r\\\\.\\
NZ729878A 2014-10-06 2015-10-05 Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alpha4beta7 integrin blocking antibodies NZ729878B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ768528A NZ768528A (en) 2014-10-06 2015-10-05 Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-α4β7 integrin blocking antibodies

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462060454P 2014-10-06 2014-10-06
PCT/US2015/054077 WO2016057424A1 (en) 2014-10-06 2015-10-05 Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies

Publications (2)

Publication Number Publication Date
NZ729878A NZ729878A (en) 2024-03-22
NZ729878B2 true NZ729878B2 (en) 2024-06-25

Family

ID=

Similar Documents

Publication Publication Date Title
HRP20210871T1 (en) Pyridopyrimdinone cdk2/4/6 inhibitors
IL273188B2 (en) Combination therapy using a chemokine receptor 2 (ccr2) antagonist and a pd-1/pd-l1 inhibitor
HRP20191268T1 (en) Thieno[2,3-c]pyrrol-4-one derivatives as erk inhibitors
JP2022191484A (en) Method of reducing neutropenia
WO2009017838A3 (en) Combinations of jak-2 inhibitors and other agents
PE20191048A1 (en) PHARMACEUTICAL DOSAGE FORMS
MX339658B (en) Combinations and methods for subcutaneous administration of immune globulin and hyaluronidase.
DK2041133T3 (en) Derivatives of imadazole [1,2-A] pyridine-2-carboxamides, their preparation and their use in therapeutics
EA200900638A1 (en) SALTS AND CRYSTAL FORMS OF 2-METHYL-2- [4- (3-METHYL-2-OXO-8-QUINOLIN-3-IL-2,3-DIHYDROIMIDAZO [4,5-c] CHINOLIN-1-IL) PHENYL] Propionitrile
IN2014MN01754A (en)
EA201000091A1 (en) DERIVATIVES OF MORFOLINOPYRIMIDINE USED IN DISEASES ASSOCIATED WITH mTOR KINASE AND / OR PI3K
IL292655A (en) Combination therapy of inhibitors of c-c chemokine receptor type 9 (ccr9) and anti-alha4beta7 integrin blocking antibodies
WO2009039988A3 (en) Use of a fibrinogen receptor antagonist and/or follicular gonadotropin releasing peptide as a therapeutic agent in the treatment of streptococcus pneumonia infection
MX2021010106A (en) Inhibitors of integrated stress response pathway.
JP2016516074A5 (en)
UA111599C2 (en) COMPOSITION OF CASPOFUNGIN
JP2017530163A5 (en)
NO20066080L (en) Treatment with irinotecan (CPT-11) and an AGFR inhibitor
MY202114A (en) Treatment of brain cancer
MX2014008284A (en) Delayed-release formulation for reducing the frequency of urination and method of use thereof.
MY173582A (en) Extended-release formulation for reducing the frequency of urination and method of use thereof
FI3463436T3 (en) A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer
AR084067A1 (en) PHARMACEUTICAL COMPOSITIONS
TR201908660T4 (en) TRIGGER OF CANCER CELLS WITH LOW-DOSE NALTREXONE.
JP2018538308A5 (en)